{
    "clinical_study": {
        "@rank": "149746", 
        "arm_group": {
            "arm_group_label": "BOTOX\u00ae", 
            "description": "Patients who receive botulinum toxin Type A (BOTOX\u00ae) treatment for Neurogenic Detrusor Overactivity as per local standard of care in clinical practice."
        }, 
        "brief_summary": {
            "textblock": "This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and\n      efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic\n      detrusor overactivity (NDO) not adequately controlled by anticholinergic drugs."
        }, 
        "brief_title": "Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX\u00ae) to Treat Neurogenic Detrusor Overactivity in Korea", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Incontinence", 
        "condition_browse": {
            "mesh_term": "Urinary Incontinence"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Patients with urinary incontinence due to NDO treated with BOTOX\u00ae as per local standard\n        of care in clinical practice.\n\n        Exclusion Criteria:\n\n        -None."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with urinary incontinence due to NDO."
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010788", 
            "org_study_id": "191622-134"
        }, 
        "intervention": {
            "arm_group_label": "BOTOX\u00ae", 
            "description": "Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity as per local standard of care in clinical practice.", 
            "intervention_name": "botulinum toxin Type A", 
            "intervention_type": "Biological", 
            "other_name": [
                "BOTOX\u00ae", 
                "onabotulinumtoxinA"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with Adverse Events and Adverse Drug Reactions", 
                "safety_issue": "No", 
                "time_frame": "4 Months"
            }, 
            {
                "measure": "International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) Total Score", 
                "safety_issue": "No", 
                "time_frame": "4 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}